First Trial Site Initiated for Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer - On May 8, 2025, the Company announced initiation of the first trial site for the OVATION ...

First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at ...

Beads were washed three times with wash buffer II (50 mM Tris-HCl (pH 7.8), 50 mM NaCl ... The resulting cDNAs were PCR-amplified using LA Taq DNA polymerase (TaKaRa), a common PCR primer used for all ...

Axions, hypothetical subatomic particles that were first proposed by theoretical physicists in the late 1970s, remain among ...

The authors confirm that telomeres in telomerase-positive cells terminate with 5'-ATC in a Pot1-dependent manner, and demonstrate that this principle holds true in telomerase-negative ALT cells as ...

The nuclear pore complex protein RANBP2 has emerged as a critical factor in the development and progression of various solid malignancies.

IRVINE, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its first ...

Q1 2025 pharma services revenue of $2.1 million, at 62% gross marginThree of the top 10 U.S. transplant centers expected to participate in clinical trialTen globally leading transplant hospitals are ...

X-ray crystallography is a technique that uses X-ray diffraction patterns to determine high-resolution, three-dimensional structures of molecules such as proteins, small organic molecules, and ...